Do GLP-1–Based Therapies Increase Cancer Risk?
Year: 2013
Type: review
Abstract: Cases of pancreatitis have been de-scribed in connection with the useof exenatide (1), liraglutide (2) and other glucagon-like peptide (GLP)-1 re-ceptor agonists. From these findings, the following hypothesis has been generated: stimulating the GLP-1 receptor with re-spective agonists has a potential to cause pancreatitis, perhaps chronic pancreati-tis, and in the long term, potentially even pancreatic cancer (3–5). Further-more, in rodents like mice and rats, stim-ulating the GLP-1 receptor raises cAMP in thyroid C cells, initiates the release of cal-citonin, and upon longer-term exposure, is accompanied by C-cell proliferation and the formation of C-cell adenomas
Source: Diabetes Care
DOI: 10.2337/dcs13-2004
Authors: Michael A. Nauck, Nele Friedrich
Institutions: Diabeteszentrum Bad Lauterberg, Universität Greifswald
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W2158762809
